Request Demo

Last update 08 May 2025

Intractable hiccups

Last update 08 May 2025

Basic Info

Synonyms

HICCOUGH INTRACTABLE, Intractable hiccups, 難治性しゃっくり

+ [1]

Introduction-

Drugs associated with Intractable hiccups

Chlorpromazine Hydrochloride

Target

DRDs

Mechanism

DRDs antagonists

Active Org.

Mitsubishi Tanabe Pharma Corp. [+1]

Originator Org.

GSK Plc

Active Indication

Vomiting [+8]

Inactive Indication

Behavioural disorders [+5]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Japan

First Approval Date31 Mar 1955

Clinical Trials associated with Intractable hiccups

CTR20211499

/ CompletedNot Applicable

盐酸氯丙嗪片在空腹及餐后条件下的人体生物等效性试验

[Translation] Bioequivalence study of chlorpromazine hydrochloride tablets in humans under fasting and fed conditions

1. 以氯丙嗪的体内药代动力学参数为生物等效性的评价指标，在中国健康受试者空腹和餐后状态下评估受试制剂（万邦德制药集团有限公司生产的盐酸氯丙嗪片，规格25mg）和参比制剂（Sanofi-Aventis Australia Pty Ltd持证的盐酸氯丙嗪片，规格25mg，商品名：Largactil®）的生物等效性 2. 观察空腹和餐后状态下口服受试制剂和参比制剂的安全性。

[Translation]

1. Using the in vivo pharmacokinetic parameters of chlorpromazine as the evaluation index of bioequivalence, the bioequivalence of the test preparation (chlorpromazine hydrochloride tablets produced by Wanbangde Pharmaceutical Group Co., Ltd., specification 25 mg) and the reference preparation (chlorpromazine hydrochloride tablets certified by Sanofi-Aventis Australia Pty Ltd, specification 25 mg, trade name: Largactil®) was evaluated in healthy Chinese subjects under fasting and fed conditions. 2. Observe the safety of oral administration of the test preparation and reference preparation under fasting and fed conditions.

Start Date07 Oct 2021

Sponsor / Collaborator

Wanbangde Pharmaceutical Holding Group Co., Ltd.

ChiCTR-IPR-17011451

/ SuspendedNot ApplicableIIT

Randomized clinical trials of ankle-wrist acupuncture treating intractable hiccup

Start Date12 Apr 2017

Sponsor / Collaborator-

NCT02943213

/ CompletedPhase 1

A Single Center, Single Dose, Open-Label, Two-Period Replicate Pilot Study to Investigate Intra-subject Variability in the Bioavailability of a Formulation Containing Chlorpromazine Hydrochloride (25 mg Sugar Coated Tablets) in at Least 16 Healthy Males and Females Under Fasting Conditions

Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD.
The aim of this pilot study is to investigate intrasubject variability in the bioavailability of Chlorpromazine Hydrochloride 25 mg sugar coated tablets.
Cycle aims to demonstrate that Chlorpromazine Hydrochloride has a shallow dose response curve and a wide safety margin. This will then allow for the modification of bioequivalence acceptance criteria in future pivotal studies which will reduce the number of participants required whilst still maintaining assurance of safety and efficacy.
Pilot Subjects (n): 20 Periods: 2 (2xR) Dosing: Single-dose Strength: 25 mg Test Product: N/A Reference: USL PHARMA Chlorpromazine Hydrochloride Analytes (in plasma): Chlorpromazine; 7-Hydroxychlorpromazine Bioequivalence based on 90% CI (Cmax, AUC): Standard; 80.00 - 125.00%

Start Date01 Nov 2016

Sponsor / Collaborator

Cycle Pharmaceuticals Ltd.

[+1]

100 Clinical Results associated with Intractable hiccups

100 Translational Medicine associated with Intractable hiccups

0 Patents (Medical) associated with Intractable hiccups

340

Literatures (Medical) associated with Intractable hiccups

01 May 2025·Journal of Stroke and Cerebrovascular Diseases

Efficacy of high-frequency peripheral magnetic stimulation in treating patients with persistent hiccups post-stroke: A retrospective study

Article

Author: Lei, Yuexiu ; Zhang, Fengxia ; Zhang, Zhan

BACKGROUNDThis study retrospectively evaluated the efficacy and safety of peripheral magnetic stimulation for treating persistent hiccups in patients after stroke.METHODSIn this retrospective study, we categorized patients with persistent hiccups post-stroke admitted to the Rehabilitation Medicine Department of Wuhan University People's Hospital between May 2022 to August 2023 into two groups. The experimental group received 10 Hz peripheral magnetic stimulation targeting the phrenic nerve, whereas the control group received a daily intramuscular injection of 10 mg metoclopramide. Treatment efficacy over a 3-day period, hiccup scores before and after treatment, and overall clinical efficacy were compared between the two groups.RESULTSSeventeen patients diagnosed with persistent hiccups post-stroke were included, with nine in the control group and eight in the experimental group. There were no significant differences between the two groups in terms of the number of hiccups, hiccup scores, or age prior to treatment. After 3 days of treatment, the clinical efficacy was 55.56 % for the control group and 100 % for the experimental group (P = 0.01). Three patients in the control group experienced adverse reactions, whereas no adverse reactions were observed in the experimental group (P = 0.036).CONCLUSIONSHigh-frequency peripheral magnetic stimulation may be more effective and associated with fewer adverse effects than metoclopramide injections for patients with intractable post-stroke hiccups. Our findings suggest a novel therapeutic strategy for managing persistent hiccups following a stroke.

07 Feb 2025·Cureus

COVID-19 Presenting With Intractable Hiccups: A Literature Review and a New Case

Article

Author: Aloqaily, Mohammed ; Ammar, Abdullah ; Aloqaily, Wafi A ; Alfarrajin, Ibrahim ; Tarazi, Alaa ; Ababneh, Raed ; Alasaad, Yousef

Hiccups manifest as involuntary and repetitive diaphragm contractions, often involving the intercostal muscles. However, the precise underlying mechanism remains incompletely understood but typically benign. During the COVID-19 pandemic, the predominant clinical presentation featured fever, cough, and dyspnea. However, multiple atypical presentations are increasingly recognized as manifestations of COVID-19, including refractory hiccups. This article aims to examine the shared characteristics, distinctions, notable correlations, and prognosis among COVID-19 patients presenting with intractable hiccups. Additionally, we present a 79-year-old male with a history of Parkinson's disease, hypertension, and diabetes who presented with refractory hiccups, cough, and a runny nose. Laboratory analysis revealed elevated inflammatory markers and a positive COVID-19 test. The patient responded well to medical management, and the hiccups were resolved. Notably, the association between persistent hiccups and COVID-19 infection is increasingly recognized, predominantly affecting older males with comorbidities and can be the sole complaint. Furthermore, we analyzed 29 cases of COVID-19 with persistent hiccups in the English literature. The mean duration of symptoms was 3.9 days with the majority of these cases being males (96.55%) and an average age of affected individuals of 58.28 years. Cough was the most frequently associated symptom (31.03%), while an equal proportion of patients (31.03%) reported intractable hiccups as their sole complaint. Additionally, common findings included elevated inflammatory markers, electrolyte imbalances, and infiltrates on imaging. Most of the patients demonstrated substantial improvement through symptomatic and medical management; however, mortality was documented in two cases, which highlights the potential for this seemingly benign manifestation to mislead and necessitate thorough evaluation upon presentation.

01 Feb 2025·Heliyon

Corrigendum to “Ultrasound-guided percutaneous laser cervical discectomy for intractable hiccups: A rare case report” [Heliyon Volume 9, Issue 3, March 2023, Article e13830]

Author: Zhou, Haocheng ; Han, Rui ; Jin, Yangqing ; Huang, Dong ; Hu, Rong ; Ma, Jiahui ; Ni, Yuncheng

[This corrects the article DOI: 10.1016/j.heliyon.2023.e13830.].

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Intractable hiccups

Basic Info

Related

Analysis